Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: Tobevibart and Elebsiran in Chronic Hepatitis B
NCT05612581Phase 2Completed
- Sponsor
- Vir Biotechnology
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Conjugated siRNA, Monoclonal Antibodies, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of tobevibart, elebsiran in Chronic Hepatitis B (CHB), sponsored by Vir Biotechnology. Started May 2023; status: completed.
02
Drugs
tobevibartelebsiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05612581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05612581.